Dr. Gabriel Peña

29/04/2026

Did you know eyelid myoclonia—usually linked to other epilepsies can actually be the main seizure type in Lafora disease? 🧠 These rare cases remind us why early genetic testing is key to uncovering hidden clues in epilepsy.
https://onlinelibrary.wiley.com/doi/10.1002/epd2.70099

14/04/2026

In a secondary analysis of the SECRETO study, over a third of young adults with cryptogenic ischemic had thrombophilia deviations at admission. https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.125.053251

13/04/2026

13/04/2026

Early Thrombolysis in Central Retinal Artery Occlusion: Stepping Toward Better Visual Outcomes?

In this post, Beatriz Sarno discusses article by Xie & Zaslavsky et al. https://www.ahajournals.org/do/10.1161/blog.20260408.485864/full/

13/04/2026

Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria: https://hubs.la/Q049w0V70

10/04/2026

Article Commentary: “Relationship Between Degree of Stenosis and Time-To-Peak Delay in High Grade Asymptomatic Carotid Artery Disease”

In this post, Natalie Neale discusses article by Marshall et al. https://www.ahajournals.org/do/10.1161/blog.20260406.761431/full/

09/04/2026

: This topical review by Terrill et al. summarizes epidemiology, mechanisms, assessment, and treatment gaps of poststroke depression and anxiety. https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.125.051664

07/04/2026

ICHD-3 Matters 🧠

Medication-overuse headache (MOH) is defined as headache on ≥15 days/month in a patient with a pre-existing primary headache, caused by regular overuse of acute medications for >3 months (≥10 days/month for triptans, ergots, opioids, or combination analgesic; ≥15 days/month for NSAIDs or paracetamol ). It usually improves after withdrawal.

To learn more, please go to: https://ichd-3.org/8-headache-attributed-to-a-substance-or-its-withdrawal/8-2-medication-overuse-headache-moh/

05/04/2026

04/04/2026

: IL-1 receptor antagonist protects neurons after stroke, but when given during tPA, plasmin degrades it, reducing benefit and increasing inflammation. Timing of neuroprotection is key: tPA first, IL-1Ra second. https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.125.054941

04/04/2026

In patients with unruptured intracranial aneurysms, postdiagnostic anxiety and depression are associated with increased rupture risk and mortality. https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.126.054546

29/03/2026

Charcot–Bouchard aneurysms (CBA):
CBA is microaneurysm (~0.05-2.5 mm) arising from small perforating arteries (~ < 0.3 mm) usually found in distal lenticulostriate arteries (LSA).
Post-mortem studies have reported a high prevalence in HTN hemorrhages

Intraparenchymal cerebral hemorrhage
https://www.facebook.com/share/p/1ApReTGWKo/

👇 Unruptureed intracranial aneurysms
https://www.facebook.com/share/p/197Tnq5d2d/

👇 Intracranial vascular malformations
https://www.facebook.com/share/p/1FqjyfCQ8X/